New 3D Mammograms to Help Detect Cancer?

In a recent vote, the Food and Drug Administration agreed to approve the Selenia Dimensions System – a new three-dimensional mammography system used to screen patients for potential breast cancer.

The system, developed by Hologic Inc., utilizes 3D images which in turn provide clearer visuals and eliminate the overlapping of tissue that was commonly seen in conventional mammograms.

Mammograms, of course, produce two-dimensional images, which at this point are becoming more and more dated. The new Hologic mammograms, though, will allow for both two- and three- dimensional screenings. This, in turn, will allow doctors to compare previous standard two-dimensional mammograms side-by-side.

"We do believe we will be able to lessen the unnecessary recalls [for more screening] and hopefully find cancer earlier and save more lives," said Robert Cascella, Hologic's chief executive.

Prior to its arrival in the U.S., this device had been approved in Europe, Asia, Latin America, Canada and Mexico.

The FDA had this to say on the matter:

Traditional mammograms are still the best way to find breast cancer, but the limited technology requires some women to have additional testing. Reviewing an additional 3-D images helped doctors find more cancers than with 2-D images alone.”

The biggest problem with the newly-approved device is the increase in radiation dose receieved by patients. However, supporters argue that because of the increased accuracy associated with detecting cancers courtesy of this device – the risk is worth it.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap